drugset / Trial / NCT00162136
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
Timeline
- Start
- 2005-09
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 10 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 35 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 45 mg/m2 | Intravenous |